The planned sites in Livonia, Las Vegas, and San Antonio would expand a partnership that places clinical research and health screenings inside Walmart stores.
|Webcasts|November 19, 2020
2020 Research Explores Clinical Trial Design and Data Collection in the New Paradigm
Author(s)Oracle
***Live: Thursday November 19, 2020 11am EST | 8am PST | 4pm GMT | 5pm CET***Join this webcast to hear the results of an industry-wide survey on the impact of the Covid-19 pandemic on clinical data collection and clinical operations. Learn how your peers have accelerated their plans to shift to a decentralized clinical trial model, and understand the benefits and challenges that come with this transition. ***On demand available after final airing until Nov. 19, 2021***
Register Free:
Event Overview: The COVID-19 pandemic has—without warning—turned clinical operations on its head, forcing the clinical research industry to re-evaluate how to manage clinical trials. In an instant, physical access to patients across the globe ceased to be an option and the impact on data collection and patient monitoring has been significant.
In this new environment, many organizations have accelerated their plans to shift to a decentralized clinical trial model. With this transition comes many benefits and challenges, and begs the question: are clinical development organizations prepared for this paradigm shift?
Oracle Health Sciences, in partnership with Informa Research, gathered insights on the impact of the COVID-19 pandemic on clinical data collection and clinical operations by conducting an industry-wide survey. The survey reveals the depth of the pandemic’s impact on clinical trials and reveals industry leaders’ future predictions for clinical development beyond 2020.
Key Learning Objectives:
- Join this webinar to learn how your peers are adapting to:
- Clinical data collection in a pandemic situation
- Regulatory challenges and concerns regarding remote data collection
- Clinical operation readiness in this new world
Speakers: Kristin Letourneau, PhD, Director of Market Research, Informa Engage
Jim Streeter, Global Vice President, Life Sciences Product Strategy, Oracle Health Sciences
Time and Date: Thursday November 19, 2020 11am EST | 8am PST | 4pm GMT | 5pm CET
On demand available after final airing until Nov. 19, 2021
Sponsor: Oracle Health Sciences
Register Free:
Related to this article
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants.
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.
In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patients in community and rural settings too often lack access to clinical research as a care option, and how closing that gap could improve outcomes and lower long-term costs.
In today’s ACT Brief, we examine why anti-kickback guidance and EHR-integrated trial matching must work together in community settings, why real-time trials depend on mature risk-based quality management, and how pharma is applying digital clones to predict outcomes.
The FDA’s RTCT initiative transmits predefined, clinically meaningful signals to regulators during active trials, so its value depends entirely on the maturity of sponsors’ upstream RBQM signal intelligence, KRIs, QTLs, and root-cause context, rather than on data speed.
In this video interview, Kent Thoelke, CEO of Paradigm Health, outlines why anti-kickback guidance and modern EHR-integrated trial matching technology must work in tandem to reach representative patient populations at the community level.
Trending on Applied Clinical Trials Online
1
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
2
What Needs to Happen Beyond the Clinical Trial Modernization Act
3
Walmart and Care Access Plan Three More Clinical Trial Centers in Michigan, Nevada, and Texas
4
Real-Time Continuous Trials Through the Lens of Risk-Based Quality Management: Why RBQM Is the Infrastructure RTCT Cannot Exist Without
5